Table 2 Odronextamab response summary according to ICR
Outcome | ICR (N = 127) |
|---|---|
Best overall response, n (%) | |
Objective response | 66 (52.0) (95% CI: 42.9–60.9) |
CR | 40 (31.5) (95% CI: 23.5–40.3) |
PR | 26 (20.5) (95% CI: 13.8–28.5) |
DOR, median, months | 10.2 (95% CI: 5.0–17.9) |
Probability of maintaining objective response at 12 months, % | 48.1 (95% CI: 35.1–59.9) |
Probability of maintaining objective response at 24 months, % | 36.9 (95% CI: 24.2–49.6) |
Duration of CR, median, months | 17.9 (95% CI: 10.2–NE) |
Probability of maintaining CR at 12 months, % | 61.5 (95% CI: 44.4–74.8) |
Probability of maintaining CR at 24 months, % | 47.2 (95% CI: 29.7–62.9) |
